Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
H3B-6545 and Palbociclib in ER+ HER2- Advanced Breast Cancer
NCT04288089Phase 1Active, not recruiting
- Sponsor
- Eisai Co., Ltd.
- Start
- Apr 2020
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of H3B-6545 in breast cancer, sponsored by Eisai Co., Ltd. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Apr 2020; status: active, not recruiting.
02
Drugs
H3B-6545
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04288089.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04288089.